Potassium Phosphates Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Potassium Phosphates Injection must be diluted and thoroughly mixed before use.
To avoid potassium or phosphorus intoxication, infuse solutions containing potassium phosphates slowly. In patients with severe renal or adrenal insufficiency, administration of Potassium Phosphates Injection may cause potassium intoxication. Infusing high concentrations of phosphorus may cause hypocalcemia, and calcium levels should be monitored.
Solutions which contain potassium ions should be used with great care if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.
In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particulary at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Potassium Phosphates Injection, USP, 3 mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of potassium (4.4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions.
There is currently no drug history available for this drug.
Potassium Phosphates Injection, USP is a sterile, nonpyrogenic, concentrated solution containing a mixture of monobasic and dibasic potassium phosphate in Water for Injection. It must be diluted prior to administration.
Each mL of the solution consists of two phosphate salts provided as follows:
|Monobasic Potassium||93 mg||170 mg|
|Phosphate -224 mg|
|Phosphate -236 mg||3 mM||4.4 mEq|
The solution contains no bacteriostatic agent or other preservative.
The solution is intended to provide phosphate ion, (PO4-3) for addition to large volume infusion fluids for intravenous use. Unused portions should be discarded.